<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Vaccine</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Kennedy expands ACIP function, membership criteria </title>
      <description>
        <![CDATA[Amending his previous two-year-renewal of the standard charter for the U.S. CDC’s Advisory Committee on Immunization Practices (ACIP), Health and Human Services Secretary Robert Kennedy made monitoring adverse vaccine events a primary function of the committee and expanded its liaison membership to include organizations that have challenged vaccine safety.>]]>
      </description>
      <guid>http://www.bioworld.com/articles/730227</guid>
      <pubDate>Fri, 10 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730227-kennedy-expands-acip-function-membership-criteria</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Vial-and-syringe-with-blue-hues.webp?t=1764971936" type="image/jpeg" medium="image" fileSize="520995">
        <media:title type="plain">Vial and syringe with blue hues</media:title>
      </media:content>
    </item>
    <item>
      <title>Kennedy sidestepping court order sidelining ACIP?</title>
      <description>
        <![CDATA[Don’t like a court order? Sidestep it. That seems to be the idea behind U.S. Health and Human Services Secretary Robert Kennedy’s latest changes to his renewal of the charter for the CDC’s Advisory Committee on Immunization Practices (ACIP).]]>
      </description>
      <guid>http://www.bioworld.com/articles/730135</guid>
      <pubDate>Tue, 07 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730135-kennedy-sidestepping-court-order-sidelining-acip</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Businessman-signing-documents.webp?t=1738961282" type="image/jpeg" medium="image" fileSize="120407">
        <media:title type="plain">Businessman signing documents</media:title>
      </media:content>
    </item>
    <item>
      <title>Supreme Court shuts the door to three life sciences petitions</title>
      <description>
        <![CDATA[What do a patent dispute over a CRISPR/Cas system, a rejected whistleblower case involving lab tests and a vaccine injury claim parading as multidistrict tort litigation have in common? All three were denied cert in the U.S. Supreme Court’s latest orders list.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729967</guid>
      <pubDate>Tue, 31 Mar 2026 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729967-supreme-court-shuts-the-door-to-three-life-sciences-petitions</link>
    </item>
    <item>
      <title>Single-dose mRNA vaccine elicits superior anti-VZV immunity in mice</title>
      <description>
        <![CDATA[Researchers from Chengdu Kanghua Biological Products Co. Ltd. recently published information on their novel varicella zoster virus (VZV) mRNA vaccine candidate (KH014). KH014 contains sequence-optimized mRNAs encoding full-length glycoprotein E encapsulated in ionizable lipid nanoparticles.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729928</guid>
      <pubDate>Thu, 26 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729928-single-dose-mrna-vaccine-elicits-superior-anti-vzv-immunity-in-mice</link>
    </item>
    <item>
      <title>Pfizer, Valneva post mixed results for Lyme disease vaccine</title>
      <description>
        <![CDATA[Overall, results from the phase III Valor trial testing Lyme disease vaccine PF-07307405 “strengthen confidence” in the candidate, according to partners Pfizer Inc. and Valneva SE, with the big pharma now looking toward regulatory submissions. Investors, however, focused on the fact that the study, which demonstrated more than 70% efficacy in preventing Lyme disease in individuals, ages 5 and older, failed to hit the statistical criterion for the first prespecified analysis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729807</guid>
      <pubDate>Mon, 23 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729807-pfizer-valneva-post-mixed-results-for-lyme-disease-vaccine</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/Syringe-and-tick.webp?t=1655757569" type="image/png" medium="image" fileSize="186953">
        <media:title type="plain">Syringe-and-tick.png</media:title>
      </media:content>
    </item>
    <item>
      <title>Emerging therapeutic strategies for Parkinson’s at ADPD 2026</title>
      <description>
        <![CDATA[Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the abnormal accumulation of α-synuclein, a protein that forms toxic aggregates and spreads between cells, damaging them. At the 20th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD), held from March 17 to 21, 2026, in Copenhagen, several strategies were presented that aim to modify the course of the disease and offer real alternatives to purely symptomatic treatments.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729789</guid>
      <pubDate>Mon, 23 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729789-emerging-therapeutic-strategies-for-parkinsons-at-adpd-2026</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Parkinsons-disease-PD-neuron-hands.webp?t=1774276432" type="image/jpeg" medium="image" fileSize="923725">
        <media:title type="plain">Art concept for Parkinson's disease</media:title>
      </media:content>
    </item>
    <item>
      <title>After judge’s injunction, will ACIP disband?</title>
      <description>
        <![CDATA[A member of the CDC’s Advisory Committee on Immunization Practices (ACIP), physician and biochemist Robert Malone, who a judge earlier this week suggested lacked vaccine-related experience, wrote March 19 on X that the committee “has been disbanded.” Nearly six hours later, he followed up, saying it was a “miscommunication.”]]>
      </description>
      <guid>http://www.bioworld.com/articles/729873</guid>
      <pubDate>Fri, 20 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729873-after-judges-injunction-will-acip-disband</link>
    </item>
    <item>
      <title>Judge’s order shuts down new vaccine schedule, ACIP itself </title>
      <description>
        <![CDATA[In one fell swoop March 16, a U.S. federal judge stayed the CDC’s January memo revising the childhood vaccine schedule and the Advisory Committee on Immunization Practices (ACIP) as reconstituted by Health and Human Services Secretary Robert Kennedy, along with everything that committee has done since early June.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729544</guid>
      <pubDate>Tue, 17 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729544-judges-order-shuts-down-new-vaccine-schedule-acip-itself</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/Gavel-stethoscope-vial-and-syringe.webp?t=1773784822" type="image/jpeg" medium="image" fileSize="407797">
        <media:title type="plain">Gavel, stethoscope, vial and syringe</media:title>
      </media:content>
    </item>
    <item>
      <title>Counterx signs license supporting work in fentanyl overdose</title>
      <description>
        <![CDATA[Counterx Therapeutics Inc. has executed an exclusive licensing agreement with the University of Minnesota and the University of Washington for a portfolio of novel monoclonal antibody and vaccine candidates targeting fentanyl and opioid overdose.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729590</guid>
      <pubDate>Wed, 11 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729590-counterx-signs-license-supporting-work-in-fentanyl-overdose</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Misc/Substance-use-opioids-overdose.webp?t=1690469144" type="image/jpeg" medium="image" fileSize="278724">
        <media:title type="plain">Various pills and powders in small plastic ziplock bags</media:title>
      </media:content>
    </item>
    <item>
      <title>Korean ARPA-H to invest ₩162B in nine projects in 2026</title>
      <description>
        <![CDATA[The K-health MIRAE Initiative, also known as Korean ARPA-H, announced plans to allocate about ₩162 billion (US$110 million) in nine new projects over the next five years, with a focus on strengthening national health security.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729582</guid>
      <pubDate>Tue, 10 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729582-korean-arpa-h-to-invest-162b-in-nine-projects-in-2026</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Korea-ARPA-H-roundtable-3-6.webp?t=1772832533" type="image/jpeg" medium="image" fileSize="642632">
        <media:title type="plain">Korea ARPA-H roundtable</media:title>
        <media:description type="plain">K-health MIRAE Initiative Director General Sun Kyung, center, and project managers at a roundtable meeting in Seoul, South Korea on March 5.</media:description>
      </media:content>
    </item>
    <item>
      <title>Replication-incompetent HAdV-55 vaccine provides in vivo protection against pathogenic adenoviruses</title>
      <description>
        <![CDATA[Aiming to develop a vaccine candidate against human adenovirus-55 (HAdV-55) infections, researchers from the First Affiliated Hospital of Guangzhou Medical University (China) and collaborators have generated a replication-incompetent rAd55-5E4.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729513</guid>
      <pubDate>Tue, 10 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729513-replication-incompetent-hadv-55-vaccine-provides-in-vivo-protection-against-pathogenic-adenoviruses</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/vaccine-research-development.webp?t=1743458404" type="image/jpeg" medium="image" fileSize="116212">
        <media:title type="plain">Vaccine vials and syringe</media:title>
      </media:content>
    </item>
    <item>
      <title>Korean ARPA-H to invest ₩162B in nine projects in 2026</title>
      <description>
        <![CDATA[The K-health MIRAE Initiative, also known as Korean ARPA-H, announced plans to allocate about ₩162 billion (US$110 million) in nine new projects over the next five years, with a focus on strengthening national health security.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729359</guid>
      <pubDate>Fri, 06 Mar 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729359-korean-arpa-h-to-invest-162b-in-nine-projects-in-2026</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Korea-ARPA-H-roundtable-3-6.webp?t=1772832533" type="image/jpeg" medium="image" fileSize="642632">
        <media:title type="plain">Korea ARPA-H roundtable</media:title>
        <media:description type="plain">K-health MIRAE Initiative Director General Sun Kyung, center, and project managers at a roundtable meeting in Seoul, South Korea on March 5.</media:description>
      </media:content>
    </item>
    <item>
      <title>Moderna to pay up to $2.25B to settle COVID-19 patents case</title>
      <description>
        <![CDATA[In what it says could be the largest disclosed patent settlement in the pharmaceutical industry, Roivant Sciences Ltd. has reached a potential $2.25 billion settlement with Moderna Inc. over the use of its lipid nanoparticle delivery technology in the Spikevax COVID-19 vaccine.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729387</guid>
      <pubDate>Wed, 04 Mar 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729387-moderna-to-pay-up-to-225b-to-settle-covid-19-patents-case</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Moderna-Spikevax-9-2.webp?t=1772645697" type="image/jpeg" medium="image" fileSize="152907">
        <media:title type="plain">Spikevax vial and product packaging</media:title>
        <media:description type="plain">Credit: Moderna Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>ACIP grows by two ahead of next meeting</title>
      <description>
        <![CDATA[The U.S. CDC’s Advisory Committee on Immunization Practices (ACIP) has two new members, bringing its total membership to 15. As he has done since dismissing the entire ACIP panel last June, Health and Human Services Secretary Robert Kennedy named the new members, Angelina Farella and Sean Downing, barely two weeks before the next ACIP meeting, March 18-19.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729272</guid>
      <pubDate>Mon, 02 Mar 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729272-acip-grows-by-two-ahead-of-next-meeting</link>
    </item>
    <item>
      <title>Moderna’s combo flu/COVID vaccine gets thumbs up in EU </title>
      <description>
        <![CDATA[The EMA’s Committee for Medicinal Products for Human Use recommended approval of Moderna Inc.’s Mcombriax (mRNA-1083), positioning it to potentially become the world’s first combination vaccine for both seasonal influenza and COVID-19.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729260</guid>
      <pubDate>Fri, 27 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729260-modernas-combo-flu-covid-vaccine-gets-thumbs-up-in-eu</link>
    </item>
    <item>
      <title>Another lawsuit challenges changes to ACIP, US vaccine schedule</title>
      <description>
        <![CDATA[U.S. Health and Human Services Secretary Robert Kennedy is facing a second lawsuit challenging his replacement of all the members of the Advisory Committee on Immunization Practices (ACIP) and seeking to undo the CDC’s Jan. 5 revision of its childhood immunization schedule.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729203</guid>
      <pubDate>Wed, 25 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729203-another-lawsuit-challenges-changes-to-acip-us-vaccine-schedule</link>
    </item>
    <item>
      <title>Australia launches world-first pediatric mRNA brain cancer trial</title>
      <description>
        <![CDATA[A world-first pediatric mRNA cancer vaccine trial is launching in Australia that could open new possibilities for children with aggressive brain tumors.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729230</guid>
      <pubDate>Tue, 24 Feb 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729230-australia-launches-world-first-pediatric-mrna-brain-cancer-trial</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Silhouette-of-child-and-brain.webp?t=1710797840" type="image/jpeg" medium="image" fileSize="185247">
        <media:title type="plain">Silhouette of child and brain</media:title>
      </media:content>
    </item>
    <item>
      <title>February ACIP meeting not happening </title>
      <description>
        <![CDATA[Amid an ongoing court challenge to the current composition of the CDC’s Advisory Committee on Immunization Practices (ACIP), the committee’s Feb. 25-27 meeting has been removed from its calendar.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729105</guid>
      <pubDate>Mon, 23 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729105-february-acip-meeting-not-happening</link>
    </item>
    <item>
      <title>&lt;em&gt;L. monocytogenes&lt;/em&gt; vaccine enhances immunotherapy efficacy in CRC</title>
      <description>
        <![CDATA[In a recent study, researchers from Stony Brook University Renaissance School of Medicine and Cold Spring Harbor Laboratory investigated whether in vivo targeting of gastrointestinal tissues via foodborne delivery of <em>Lm</em>-based cancer vaccines could control tumor growth in murine models of colorectal cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728976</guid>
      <pubDate>Mon, 23 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728976-eml-monocytogenes-em-vaccine-enhances-immunotherapy-efficacy-in-crc</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Colorectal-cancer-3D-illustration.webp?t=1704985372" type="image/jpeg" medium="image" fileSize="302450">
        <media:title type="plain">Colorectal cancer 3D illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Moderna’s flu vaccine back in play as FDA shifts course on review</title>
      <description>
        <![CDATA[A week after catching Moderna Inc. and its investors off guard with a refuse-to-file letter, the U.S. FDA has reversed course on the company’s BLA submission seeking approval of seasonal influenza vaccine mRNA-1010, now agreeing to review the application and setting an assigned PDUFA date of Aug. 5, 2026.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729070</guid>
      <pubDate>Wed, 18 Feb 2026 12:05:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729070-modernas-flu-vaccine-back-in-play-as-fda-shifts-course-on-review</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/FDA-vaccine-illustration.webp?t=1603308073" type="image/png" medium="image" fileSize="381594">
        <media:title type="plain">FDA vaccine illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Australia launches world-first pediatric mRNA brain cancer trial</title>
      <description>
        <![CDATA[A world-first pediatric mRNA cancer vaccine trial is launching in Australia that could open new possibilities for children with aggressive brain tumors. The Paedneo-Vax trial, funded by Canada’s Providence Therapeutics Holdings Inc., in combination with the Australian Government and philanthropic donors, is the first multisite pediatric study to evaluate individualized mRNA vaccines designed specifically for each child's cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728862</guid>
      <pubDate>Fri, 13 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728862-australia-launches-world-first-pediatric-mrna-brain-cancer-trial</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Silhouette-of-child-and-brain.webp?t=1710797840" type="image/jpeg" medium="image" fileSize="185247">
        <media:title type="plain">Silhouette of child and brain</media:title>
      </media:content>
    </item>
    <item>
      <title>DNA origami vaccine produces broadly neutralizing HIV antibodies</title>
      <description>
        <![CDATA[The use of DNA scaffolds could mark a turning point in HIV vaccine design. Scientists at Scripps Research and the Massachusetts Institute of Technology (MIT) have created a new vaccine platform based on DNA origami, a material that the immune system does not recognize as a threat, avoiding unwanted responses.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728827</guid>
      <pubDate>Fri, 13 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728827-dna-origami-vaccine-produces-broadly-neutralizing-hiv-antibodies</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-source/DNA-based-vaccine-MIT-Scripps-hero.webp?t=1770996481" type="image/jpeg" medium="image" fileSize="646327">
        <media:title type="plain">Illustration of DNA-based vaccine for HIV</media:title>
        <media:description type="plain">The DNA-based vaccine induces antibodies to the HIV antigen (blue) without eliciting antibodies to the DNA particle (gray), whereas the protein-based vaccine generates antibodies to both the HIV antigen (blue) and the protein particle (red). Image created by Grant Knappe (MIT) based on atomic models from MIT (DNA-based vaccine) and Scripps Research (protein-based vaccine). Credits: MIT and Scripps Research</media:description>
      </media:content>
    </item>
    <item>
      <title>Leave it to CBER: Prasad squad socks Moderna with flu RTF</title>
      <description>
        <![CDATA[Moderna Inc. blamed a switcheroo by the U.S. FDA for the refusal-to-file (RTF) letter on the seasonal influenza vaccine mRNA-1010. Shares of the firm (NASDAQ:MRNA) closed Feb. 11 at $40.51, down $1.49, having traded as low as $36.66 as investors learned of the RTF letter, which Moderna said is “inconsistent with feedback” the company was given by regulators during pre-phase III as well as pre-BLA-submission talks.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728726</guid>
      <pubDate>Wed, 11 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728726-leave-it-to-cber-prasad-squad-socks-moderna-with-flu-rtf</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Syringe-in-front-of-Moderna-logo.webp?t=1718054196" type="image/jpeg" medium="image" fileSize="96455">
        <media:title type="plain">Syringe in front of Moderna logo</media:title>
        <media:description type="plain">Credit: Asiraj - stock.adobe.com</media:description>
      </media:content>
    </item>
    <item>
      <title>Diff Biotech’s DIFF-flu influenza vaccine cleared to enter clinic</title>
      <description>
        <![CDATA[Zhejiang Difference Biological Technology Co. Ltd. (Diff Biotech)’s proprietary nasal spray influenza attenuated live vaccine, DIFF-flu, has received clinical trial approval from China’s National Medical Products Administration (NMPA).]]>
      </description>
      <guid>http://www.bioworld.com/articles/728766</guid>
      <pubDate>Tue, 10 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728766-diff-biotechs-diff-flu-influenza-vaccine-cleared-to-enter-clinic</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Close-up-of-nasal-spray.webp?t=1694529016" type="image/jpeg" medium="image" fileSize="215542">
        <media:title type="plain">Close-up of nasal drug spraying</media:title>
      </media:content>
    </item>
    <item>
      <title>Delonix gains clinical trial clearances for MenB vaccine DX-104</title>
      <description>
        <![CDATA[Delonix Bioworks Ltd. has obtained IND clearance from China’s National Medical Products Administration (NMPA) for its group B meningococcal (MenB) vaccine candidate, DX-104. This follows the successful completion last month of clinical trial notification (CTN) procedures and ethics committee approval in Australia.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728742</guid>
      <pubDate>Mon, 09 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728742-delonix-gains-clinical-trial-clearances-for-menb-vaccine-dx-104</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Vaccine-research-vial-syringe.webp?t=1670859743" type="image/png" medium="image" fileSize="1080600">
        <media:title type="plain">Vaccine vial and syringe</media:title>
      </media:content>
    </item>
    <item>
      <title>Intranasal adenoviral H5N1 vaccine protects naive and previously vaccinated rodents</title>
      <description>
        <![CDATA[A recent publication in <em>Cell Reports Medicine</em> from researchers at the Washington University School of Medicine and the La Jolla Institute for Immunology presents a promising new strategy for H5N1 vaccination.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728634</guid>
      <pubDate>Thu, 05 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728634-intranasal-adenoviral-h5n1-vaccine-protects-naive-and-previously-vaccinated-rodents</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/NIAID-CDC-H5N1-Avian-Influenza.webp?t=1738592965" type="image/jpeg" medium="image" fileSize="368973">
        <media:title type="plain">Photo of bird, H5N1 virus</media:title>
        <media:description type="plain">H5N1 bird flu is widespread in wild birds worldwide. Credit: NIAID and CDC. License: CC BY 2.0</media:description>
      </media:content>
    </item>
    <item>
      <title>Kahimmune Therapeutics signs licensing agreement</title>
      <description>
        <![CDATA[Kahimmune Therapeutics SAS has signed an exclusive licensing agreement with Gustave Roussy and SATT Paris-Saclay. Created at the end of last year as a spin-off of Gustave Roussy and SATT Paris-Saclay, Kahimmune builds on the latest discoveries in immunology relating to the dark genome.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728510</guid>
      <pubDate>Tue, 03 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728510-kahimmune-therapeutics-signs-licensing-agreement</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Deal-illustration1.webp?t=1613684293" type="image/png" medium="image" fileSize="542426">
        <media:title type="plain">Handshake with DNA, molecules</media:title>
      </media:content>
    </item>
    <item>
      <title>US childhood vaccines trapped in the crosshairs of trust </title>
      <description>
        <![CDATA[Although the American Academy of Pediatrics has been releasing guidances on vaccines for decades, the 2026 immunization schedule it issued Jan. 26 is creating some buzz given the U.S. CDC’s newly abbreviated childhood schedule that removed several routine recommendations.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728334</guid>
      <pubDate>Tue, 27 Jan 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728334-us-childhood-vaccines-trapped-in-the-crosshairs-of-trust</link>
    </item>
    <item>
      <title>Asia roundup: Shionogi ups Viiv stake, Fosun spinoff plans, more </title>
      <description>
        <![CDATA[Shionogi & Co. Ltd. and Fosun Pharmaceutical (Group) Co. Ltd. were involved in separate divestment transactions this week, with Shionogi buying out Pfizer Inc.’s stake in Viiv Healthcare Ltd. to lift its holding to 21.7%.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728501</guid>
      <pubDate>Tue, 27 Jan 2026 00:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728501-asia-roundup-shionogi-ups-viiv-stake-fosun-spinoff-plans-more</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Global-handshake-silhouette.webp?t=1670353285" type="image/png" medium="image" fileSize="178881">
        <media:title type="plain">Global handshake silhouette</media:title>
      </media:content>
    </item>
    <item>
      <title>Asia roundup: Shionogi ups Viiv stake, Fosun spinoff plans, more </title>
      <description>
        <![CDATA[Shionogi & Co. Ltd. and Fosun Pharmaceutical (Group) Co. Ltd. were involved in separate divestment transactions this week, with Shionogi buying out Pfizer Inc.’s stake in Viiv Healthcare Ltd. to lift its holding to 21.7%.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728173</guid>
      <pubDate>Fri, 23 Jan 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728173-asia-roundup-shionogi-ups-viiv-stake-fosun-spinoff-plans-more</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Global-handshake-silhouette.webp?t=1670353285" type="image/png" medium="image" fileSize="178881">
        <media:title type="plain">Global handshake silhouette</media:title>
      </media:content>
    </item>
  </channel>
</rss>
